Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Targets in African-American Youth With Type 2 Diabetes
NCT02960659Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2017
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Change in Absolute Gluconeogenesis From Baseline to 12 Weeks. Started May 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02960659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960659.